Clinical Trials Sponsored by ACT Genomics

Total 7344 results

Gustave Roussy, Cancer Campus, Grand Paris
BeiGene; C2i Genomics

Not yet recruiting

tislelizUMaB in canceR Patients With molEcuLar residuaL Disease (UMBRELLA)

Soft Tissue Sarcoma | Cancer | Lung Cancer | Pancreas Cancer | Colo-rectal Cancer

France
Translational Genomics Research Institute
United States Department of Defense

Completed

Studies in Patients With Tuberous Sclerosis Complex

Tuberous Sclerosis Complex

United States
Genomics PLC
NHS North of England Commissioning Support (NECS)

Completed

The Healthcare Evaluation of Absolute Risk Testing Study (HEART)

Cardiovascular Diseases

United Kingdom
Singlera Genomics Inc.
The First Hospital of Jilin University

Recruiting

Refinement and Validation of a Diagnostic Model (GAMAD) for Early Detection of Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Coral Genomics, Inc.
National Human Genome Research Institute (NHGRI)

Terminated

Predicting Medication Response for Autoimmune Disease (REEF)

Rheumatoid Arthritis | Psoriasis | Crohn's Disease | Ulcerative Colitis

United States
University of California, San Francisco
Translational Genomics Research Institute

Completed

Molecular Profiling for Individualized Treatment Plan for DIPG

Diffuse Intrinsic Pontine Glioma (DIPG)

United States
Bionano Genomics
Columbia University; University of Iowa; Medical College of Wisconsin; Augusta... and other collaborators

Recruiting

Validation of Optical Genome Mapping for the Identification of Constitutional Genomic Variants in a Postnatal Cohort

Intellectual Disability | Autism Spectrum Disorder | Fragile X Syndrome | Developmental Disability | Congenital Anomaly | Facioscapulohumeral Muscular Dystrophy 1

United States
ReCode Therapeutics
Sano Genetics; Reverba

Recruiting

A Study Providing Genetic Testing to Find Those Who May Have Primary Ciliary Dyskinesia for Potential Clinical Trials

Primary Ciliary Dyskinesia

United States
Neuracle Genetics, Inc
ORA, Inc.

Recruiting

NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration

Age-Related Macular Degeneration

Canada
NewLink Genetics Corporation

Completed

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

Metastatic Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
NewLink Genetics Corporation

Completed

Vaccine Treatment for Surgically Resected Pancreatic Cancer

Pancreatic Cancer

United States
NewLink Genetics Corporation

Terminated

IDO Inhibitor Study for Relapsed or Refractory Solid Tumors (D-1MT)

Melanoma | Breast Cancer | Pancreatic Cancer | Lung Cancer | Solid Tumors

United States
NewLink Genetics Corporation

Completed

Oral Bioavailability,and Food Effect Study and Single Ascending Dose PK Study in Healthy Male Volunteers

Healthy

Canada
NewLink Genetics Corporation

Terminated

Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer

Pancreatic Cancer | Pancreatic Carcinoma Non-resectable

United States
NewLink Genetics Corporation

Terminated

Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (PILLAR)

Pancreatic Cancer | Locally Advanced Malignant Neoplasm | Pancreatic Carcinoma Non-resectable

United States
NewLink Genetics Corporation

Terminated

Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer

Pancreatic Cancer

United States
NewLink Genetics Corporation

Completed

Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers (NLG2111)

Healthy

United States
NewLink Genetics Corporation

Completed

Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors

Cancer | Solid Tumor

United States
NewLink Genetics Corporation

Terminated

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Recurrent | Progression of Non-small Cell Lung Cancer

United States
University Hospital, Montpellier
Genomic Institute of Montpellier

Not yet recruiting

Multimodal Investigation of Intracranial Clot Environment (MISO)

Brain Ischemia | Acute Ichemic Stroke
Berry Genomics Co., Ltd.
Shanghai Chest Hospital; Baotou Cancer Hospital

Unknown

cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China

Adenocarcinoma | Nonsmall Cell Lung Cancer

China
Mercer University
Merck Sharp & Dohme LLC; Emory University; Celera Genomics

Completed

Study of Cholesterol Levels and Types in African Americans With Type 2 Diabetes (LAAD)

Type 2 Diabetes | Cholesterol | African American | Lipoprotein | Apolipoprotein

United States
NewLink Genetics Corporation

Terminated

Immunotherapy Study for Patients With Stage IV Melanoma

Metastatic Melanoma | Stage IV Melanoma

United States
NewLink Genetics Corporation

Terminated

A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma (NLG2107)

Melanoma

United States
NewLink Genetics Corporation

Completed

Immunotherapy Study for Metastatic Renal Cell Cancer

Metastatic Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Metastatic Kidney Cancer | Refractory Renal Cell Carcinoma | Metastatic Clear-cell Renal Cancer

United States
NewLink Genetics Corporation

Completed

NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors

Solid Tumor

United States
NewLink Genetics Corporation

Completed

A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
NewLink Genetics Corporation

Completed

A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Russian Federation, Ukraine
NewLink Genetics Corporation

Completed

Vaccine Treatment for Advanced Malignant Melanoma

Malignant Melanoma

United States
NewLink Genetics Corporation

Completed

Vaccine Treatment for Hormone Refractory Prostate Cancer

Prostate Cancer

United States
NewLink Genetics Corporation

Completed

CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)

Metastatic Renal Cell Carcinoma

Korea, Republic of, United States
NewLink Genetics Corporation

Terminated

A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Ovarian Cancer

United States
NewLink Genetics Corporation

Completed

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

Glioma | Glioblastoma Multiforme | Gliosarcoma | Malignant Brain Tumor

United States
NewLink Genetics Corporation

Terminated

Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy

Pancreatic Cancer

United States
NewLink Genetics Corporation

Terminated

Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Recurrent | Progression of Non-small Cell Lung Cancer

United States
NewLink Genetics Corporation

Withdrawn

Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.

Cancer | Ovarian Cancer | Solid Tumor

United States
NewLink Genetics Corporation

Terminated

Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors

Advanced Solid Tumor Malignancy

United States
NewLink Genetics Corporation

Completed

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Glioma | Glioblastoma Multiforme | Gliosarcoma | Ependymoma | Medulloblastoma | Diffuse Intrinsic Pontine Glioma | Malignant Brain Tumor | Primary CNS Tumor

United States
NewLink Genetics Corporation

Completed

Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma | Metastatic Pancreatic Cancer

United States
NewLink Genetics Corporation

Terminated

Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors

Solid Tumors

United States
NewLink Genetics Corporation

Completed

Vaccine Study for Surgically Resected Pancreatic Cancer

Pancreatic Cancer

United States
NewLink Genetics Corporation

Terminated

Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
NewLink Genetics Corporation

Completed

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Pancreatic Cancer

United States
NewLink Genetics Corporation

Completed

Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer

Metastatic Breast Cancer

United States, Poland
NewLink Genetics Corporation

Terminated

Vaccine Treatment for Advanced Breast Cancer

Breast Cancer

United States
Illumina, Inc.
Reprogenetics; Genesis Genetics

Completed

Single Embryo TrAnsfeR of Euploid Embryo (STAR)

Infertility | Aneuploidy

United States, Canada, Australia, United Kingdom
John P. Hussman Institute for Human Genomics
University of Miami

Unknown

Genetics of Neural Tube Defects (NTD)

Neural Tube Defects

United States
Guangdong Provincial Hospital of Traditional Chinese...
Beijing Genomics Institute

Unknown

Impact of Traditional Chinese Medicine on the Gut Microbiota-dependent Trimethylamine N-oxide (TCM-TMAO)

Acute Coronary Syndrome

China
NSABP Foundation Inc
Pfizer; Genomic Health®, Inc.

Completed

Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer

Breast Cancer

United States, Canada
Sunnybrook Health Sciences Centre
Genomic Health®, Inc.

Completed

The Impact of the Oncotype DX® Breast Cancer Assay on Treatment Decisions in a Canadian Population

Hormone Receptor Positive Malignant Neoplasm of Breast

Canada

Clinical Trials Sponsored by ACT Genomics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations